Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

NOTE: If you attended this live CE activity that was held on September 26, 2018 during the NASP Annual Meeting & Expo in Washington, DC AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-18-356-L04-P), you are ineligible to also receive CE credit for this home-study activity.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities►

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). This activity was originally presented during the 2018 National Association of Specialty Pharmacy Annual Meeting & Expo held in Washington, DC. This activity is an engaging, detailed guide into technology use cases being employed in the market, how they are making dramatic differences in how pharmacists interact with patients, and the results from those interactions.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

• Recognize HIPAA related limitations of SMS messaging.
• Discuss barriers to patient adoption of self-service tools such as apps and websites.
• Explain how mobile messaging and engagement can improve healthcare quality.
• List useful applications of patient reported data.

Faculty

Michael T. Einodshofer, RPh, MBA
Chief Innovation Officer
Maxor National Pharmacy Services

Dan Sweeney
Vice President
Specialty Pharmacy Relay Network, LLC

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Michael T. Einodshofer is the Chief Innovation Officer of Maxor, and a stock shareholder of BioMarin, Celgene, and Ultragenyx. Dan Sweeney does not have any relevant financial and/or commercial relationships to disclose.

The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 6-13-2019
Expiration Date: 6-13-2022

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-192-H04-P has been assigned to this knowledge-based home-study CE activity (initial release date 6-13-19). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.